Cargando…

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors

SIMPLE SUMMARY: Fluoropyrimidines represent the backbone of many combination chemotherapy regimens for the treatment of solid cancers but are still associated with toxicity and mechanisms of resistance. In this review, we focused on the epigenetic modifiers histone deacetylase inhibitors (HDACis) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grumetti, Laura, Lombardi, Rita, Iannelli, Federica, Pucci, Biagio, Avallone, Antonio, Di Gennaro, Elena, Budillon, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833539/ https://www.ncbi.nlm.nih.gov/pubmed/35158962 http://dx.doi.org/10.3390/cancers14030695

Ejemplares similares

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
por: Iannelli, Federica, et al.
Publicado: (2020)

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
por: Lombardi, Rita, et al.
Publicado: (2021)

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
por: Milone, Maria Rita, et al.
Publicado: (2014)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
por: Roca, Maria Serena, et al.
Publicado: (2019)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol
por: Avallone, Antonio, et al.
Publicado: (2020)

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid
por: Bizzarro, Valentina, et al.
Publicado: (2015)

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
por: Ciardiello, Chiara, et al.
Publicado: (2019)

Tissue transglutaminase: a new target to reverse cancer drug resistance
por: Budillon, Alfredo, et al.
Publicado: (2011)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles
por: Ciardiello, Chiara, et al.
Publicado: (2018)

Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection
por: Costantini, Susan, et al.
Publicado: (2023)

Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy
por: Del Re, Marzia, et al.
Publicado: (2014)

An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer
por: Costantini, Susan, et al.
Publicado: (2022)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
por: Shklovskaya, Elena, et al.
Publicado: (2021)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor
por: Xie, Ya-Jia, et al.
Publicado: (2023)

Epigenetics and Helicobacter pylori
por: Capparelli, Rosanna, et al.
Publicado: (2022)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients
por: Lapucci, Andrea, et al.
Publicado: (2021)

Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
por: Ciernikova, Sona, et al.
Publicado: (2020)

How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain: A Single Center Approach
por: Padegimas, Allison, et al.
Publicado: (2020)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tian, Wei, et al.
Publicado: (2023)

Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors
por: Ajani, Jaffer A., et al.
Publicado: (2020)

Sequential PET/CT with [(18)F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis
por: Pecori, Biagio, et al.
Publicado: (2017)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

A narrative review of genetic factors affecting fluoropyrimidine toxicity
por: Gmeiner, William H.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6mh2cbmqf3bskidkrojoj3o9f